Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Recently diagnosed with thyroid eye disease? You may want to know about a new clinical study

(BPT) - Your eyes can tell you a lot about your health, and this is especially true for those living with thyroid eye disease (TED). TED occurs when the immune system mistakenly targets the tissues around the eyes, leading to symptoms like swelling, bulging and discomfort. During the active phase of TED, when these symptoms are most pronounced, people often experience redness, pain, and inflammation, which can impact daily life.

TED is commonly associated with Graves' disease, an autoimmune condition where the immune system attacks the thyroid gland. According to the American Thyroid Association, TED can manifest symptoms such as a gritty sensation in the eyes, light sensitivity, dry eyes, and even double vision. While these symptoms may vary in intensity and can improve over time, some individuals may experience more severe forms that require prescription medication or, in some situations, surgery.

A new investigational drug

In an effort to develop additional drug options for TED, researchers are conducting a clinical trial called the spiriTED study. This study is focused on evaluating an investigational drug, TOUR006, in adults with Graves' disease whose onset of TED symptoms began in the past 15 months. The goal is to better understand how TOUR006 may work in comparison to a placebo - a substance without any active investigational drug.

How to participate in the spiriTED study

Current treatments for conditions like TED exist thanks to the participation of research study volunteers. If you or someone you know is managing moderate to severe active-phase TED, you might consider joining the spiriTED study to help advance research efforts for yourself and others facing similar challenges.

To be eligible, participants must be between 18 and 80 years old, have been diagnosed with Graves' disease and are currently experiencing moderate to severe symptoms of TED that began in the last 15 months. Note that this is not a complete list of study eligibility requirements. The study doctor will review the full requirements for this study with you. You may be eligible for reasonable compensation for your time to attend study visits and/or reimbursement for certain approved study-related costs, such as transportation. Your safety is a top priority, and you'll be monitored throughout the study.

To learn more and see if you qualify, click here to take the next step.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.